Evidence map›Paper›PMID 41271870›Full record

ArticleScientific reports2025

Multimodal deep learning framework integrating multiphase CT and histopathological whole slide imaging for predicting recurrence in ccRCC.

Changyi Ma, Bao Feng, Yan Lei, Zhaole Yu, Yu Liu, Jin Cui, Rong-Gang Li, Xiufang Huang, Baiming Wu, Zhixin Luo and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Changyi Ma *Department of Radiology, Jiangmen Central Hospital, 23 Beijie Haibang Street, Jiangmen, People's Republic of China.
Bao Feng *School of Electronic Information and Automation, Guilin University of Aerospace Technology, 2 Jinji Road, Guilin, People's Republic of China.
Yan LeiDepartment of Radiology, Jiangmen Central Hospital, 23 Beijie Haibang Street, Jiangmen, People's Republic of China.
Zhaole YuSchool of Electronic Information and Automation, Guilin University of Aerospace Technology, 2 Jinji Road, Guilin, People's Republic of China.
Yu LiuSchool of Electronic Information and Automation, Guilin University of Aerospace Technology, 2 Jinji Road, Guilin, People's Republic of China.
Jin CuiDepartment of Radiology, Jiangmen Central Hospital, 23 Beijie Haibang Street, Jiangmen, People's Republic of China.
Rong-Gang LiDepartment of Pathology, Jiangmen Central Hospital, 23 Beijie Haibang Street, Jiangmen, People's Republic of China.
Xiufang HuangDepartment of Pathology, Jiangmen Central Hospital, 23 Beijie Haibang Street, Jiangmen, People's Republic of China.
Baiming WuDepartment of Radiology, Jiangmen Central Hospital, 23 Beijie Haibang Street, Jiangmen, People's Republic of China.
Zhixin LuoDepartment of Radiology, Jiangmen Central Hospital, 23 Beijie Haibang Street, Jiangmen, People's Republic of China.
Enming CuiDepartment of Radiology, Jiangmen Central Hospital, 23 Beijie Haibang Street, Jiangmen, People's Republic of China. cem2008@163.com.

Funding

Guangdong Basic and Applied Basic Research Foundation 2021A1515220080Jiangmen Science and Technology Plan Program 2024YL01033
6 · The paper itself

Abstract

ccRCC is an aggressive, heterogeneous tumor with a poor prognosis. Prognostic assessments need multi-modal data. Radiological images have limits, while pathological images offer micro-level details. Integrating these for ccRCC outcome prediction is important. Our study aimed to develop and validate a DL fusion model using multiphase CT images and WSI for postoperative risk stratification in ccRCC patients. This retrospective study included 274 ccRCC patients who underwent multiphase CT scans (Jan 2008-Mar 2021), with diagnoses confirmed by histopathology post-surgery. The patient cohort was divided into a training cohort of 164 patients for model development and a test cohort of 110 patients for model validation. The primary outcome was local recurrence or metastasis versus non-recurrence (NR) with a minimum follow-up of 3 years. DL models based on multiphase CT images and histopathological WSIs were developed and validated. Performance comparisons among models were made through accuracy (ACC) and receiver operating characteristic (ROC) curve analyses, with integrated discrimination improvement (IDI) analysis and the DeLong test assessing diagnostic performance. Decision curve analysis (DCA) evaluated clinical utility, and Kaplan-Meier analysis assessed variable-survival correlations. The CT and Pathology Mutual Guidance Fusion Diagnostic Network (CPNet) exhibited superior performance in predicting postoperative disease-free survival (DFS) in ccRCC patients. Among the models, the PCP-Pathology Fuse model achieved the highest AUC of 0.8363 and accuracy of 75.45%, outperforming the CMP-Pathology Fuse (AUC 0.7965, ACC 69.09%) and NP-Pathology Fuse (AUC 0.798, ACC 69.09%) models. Its performance was comparable to the Three-phase-Pathology Fuse model (AUC 0.8341, ACC 70.00%, P > 0.05). IDI and DCA confirmed significant net benefits (0.01-0.95) for the PCP-based model. The PCP-based CPNet model shows promise for predicting postoperative DFS in ccRCC patients, with performance comparable to three-phase CT-pathology models. It may serve as a potential bioimaging prognostic marker, pending external validation to support clinical integration.

Indexed as

Deep LearningKidney NeoplasmsNeoplasm Recurrence, LocalTomography, X-Ray ComputedAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesROC CurveArtificial intelligencePathologyPrognosisRenal cell carcinomaX-ray computed tomography

Identifiers

PMID41271870
PMCPMC12638770

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.